annual FCF:
$468.37M+$95.09M(+25.47%)Summary
- As of today (June 22, 2025), HALO annual free cash flow is $468.37 million, with the most recent change of +$95.09 million (+25.47%) on December 31, 2024.
- During the last 3 years, HALO annual FCF has risen by +$170.38 million (+57.18%).
- HALO annual FCF is now at all-time high.
Performance
HALO Free cash flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly FCF:
$153.27M-$22.14M(-12.62%)Summary
- As of today (June 22, 2025), HALO quarterly free cash flow is $153.27 million, with the most recent change of -$22.14 million (-12.62%) on March 31, 2025.
- Over the past year, HALO quarterly FCF has increased by +$27.39 million (+21.76%).
- HALO quarterly FCF is now -12.62% below its all-time high of $175.41 million, reached on December 31, 2024.
Performance
HALO quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
$495.76M+$27.39M(+5.85%)Summary
- As of today (June 22, 2025), HALO TTM free cash flow is $495.76 million, with the most recent change of +$27.39 million (+5.85%) on March 31, 2025.
- Over the past year, HALO TTM FCF has increased by +$72.19 million (+17.04%).
- HALO TTM FCF is now at all-time high.
Performance
HALO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free cash flow Formula
FCF = Cash From Operations − CAPEX
HALO Free cash flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +25.5% | +21.8% | +17.0% |
| 3 y3 years | +57.2% | +224.0% | +72.6% |
| 5 y5 years | +623.5% | +3191.4% | +656.6% |
HALO Free cash flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +99.0% | -12.6% | +290.4% | at high | +110.7% |
| 5 y | 5-year | at high | +623.5% | -12.6% | +3191.4% | at high | +656.6% |
| alltime | all time | at high | +623.5% | -12.6% | +599.4% | at high | +654.1% |
HALO Free cash flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $153.27M(-12.6%) | $495.76M(+5.8%) |
| Dec 2024 | $468.37M(+25.5%) | $175.41M(+54.1%) | $468.37M(+19.3%) |
| Sep 2024 | - | $113.86M(+114.0%) | $392.71M(-3.8%) |
| Jun 2024 | - | $53.21M(-57.7%) | $408.32M(-3.6%) |
| Mar 2024 | - | $125.88M(+26.2%) | $423.57M(+13.5%) |
| Dec 2023 | $373.28M(+58.6%) | $99.76M(-22.9%) | $373.28M(+5.6%) |
| Sep 2023 | - | $129.47M(+89.1%) | $353.63M(+20.8%) |
| Jun 2023 | - | $68.47M(-9.4%) | $292.79M(+11.1%) |
| Mar 2023 | - | $75.59M(-5.6%) | $263.58M(+12.0%) |
| Dec 2022 | $235.30M(-21.0%) | $80.11M(+16.7%) | $235.30M(-0.9%) |
| Sep 2022 | - | $68.63M(+74.8%) | $237.55M(-18.1%) |
| Jun 2022 | - | $39.26M(-17.0%) | $290.17M(+1.0%) |
| Mar 2022 | - | $47.31M(-42.6%) | $287.26M(-3.6%) |
| Dec 2021 | $297.98M(+462.8%) | $82.36M(-32.1%) | $297.98M(+12.5%) |
| Sep 2021 | - | $121.24M(+233.5%) | $264.85M(+77.1%) |
| Jun 2021 | - | $36.36M(-37.3%) | $149.51M(+29.0%) |
| Mar 2021 | - | $58.03M(+17.9%) | $115.93M(+118.9%) |
| Dec 2020 | $52.95M(-159.2%) | $49.22M(+733.1%) | $52.95M(-325.0%) |
| Sep 2020 | - | $5.91M(+112.6%) | -$23.54M(-60.9%) |
| Jun 2020 | - | $2.78M(-156.1%) | -$60.14M(-32.5%) |
| Mar 2020 | - | -$4.96M(-81.8%) | -$89.07M(-0.4%) |
| Dec 2019 | -$89.46M(+65.2%) | -$27.27M(-11.2%) | -$89.46M(+63.2%) |
| Sep 2019 | - | -$30.69M(+17.4%) | -$54.81M(+26.4%) |
| Jun 2019 | - | -$26.15M(+388.8%) | -$43.38M(+18.8%) |
| Mar 2019 | - | -$5.35M(-172.4%) | -$36.50M(-32.6%) |
| Dec 2018 | -$54.16M(-140.8%) | $7.39M(-138.4%) | -$54.16M(-159.6%) |
| Sep 2018 | - | -$19.26M(-0.1%) | $90.84M(-30.2%) |
| Jun 2018 | - | -$19.28M(-16.2%) | $130.19M(-1.6%) |
| Mar 2018 | - | -$23.02M(-115.1%) | $132.25M(-0.3%) |
| Dec 2017 | $132.70M(-348.0%) | $152.39M(+658.2%) | $132.70M(-469.6%) |
| Sep 2017 | - | $20.10M(-216.7%) | -$35.90M(-44.9%) |
| Jun 2017 | - | -$17.23M(-23.6%) | -$65.17M(+5.2%) |
| Mar 2017 | - | -$22.56M(+39.1%) | -$61.96M(+15.8%) |
| Dec 2016 | -$53.52M(+35.7%) | -$16.21M(+76.8%) | -$53.52M(-1.1%) |
| Sep 2016 | - | -$9.17M(-34.5%) | -$54.14M(-13.1%) |
| Jun 2016 | - | -$14.01M(-0.8%) | -$62.29M(+57.3%) |
| Mar 2016 | - | -$14.12M(-16.1%) | -$39.60M(+0.4%) |
| Dec 2015 | -$39.44M(-19.3%) | -$16.83M(-2.8%) | -$39.44M(+65.8%) |
| Sep 2015 | - | -$17.32M(-299.6%) | -$23.79M(+18.8%) |
| Jun 2015 | - | $8.68M(-162.1%) | -$20.02M(-55.3%) |
| Mar 2015 | - | -$13.97M(+1088.9%) | -$44.81M(-8.3%) |
| Dec 2014 | -$48.89M(-5.3%) | -$1.18M(-91.3%) | -$48.89M(-24.0%) |
| Sep 2014 | - | -$13.55M(-15.9%) | -$64.29M(+1.3%) |
| Jun 2014 | - | -$16.12M(-10.7%) | -$63.47M(+8.7%) |
| Mar 2014 | - | -$18.04M(+8.8%) | -$58.39M(+13.1%) |
| Dec 2013 | -$51.64M | -$16.58M(+30.1%) | -$51.64M(-1.6%) |
| Sep 2013 | - | -$12.74M(+15.4%) | -$52.47M(-3.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$11.04M(-2.2%) | -$54.19M(-5.9%) |
| Mar 2013 | - | -$11.28M(-35.2%) | -$57.62M(-12.3%) |
| Dec 2012 | -$65.69M(+87.0%) | -$17.41M(+20.3%) | -$65.69M(+5.4%) |
| Sep 2012 | - | -$14.47M(+0.0%) | -$62.34M(+1.6%) |
| Jun 2012 | - | -$14.46M(-25.3%) | -$61.36M(+42.1%) |
| Mar 2012 | - | -$19.36M(+37.7%) | -$43.19M(+23.0%) |
| Dec 2011 | -$35.13M(-23.7%) | -$14.06M(+4.3%) | -$35.13M(+22.1%) |
| Sep 2011 | - | -$13.48M(-463.5%) | -$28.77M(+6.7%) |
| Jun 2011 | - | $3.71M(-132.8%) | -$26.97M(-39.5%) |
| Mar 2011 | - | -$11.30M(+46.6%) | -$44.58M(-3.2%) |
| Dec 2010 | -$46.03M(+10.6%) | -$7.71M(-34.0%) | -$46.03M(-7.7%) |
| Sep 2010 | - | -$11.68M(-16.0%) | -$49.86M(-5.6%) |
| Jun 2010 | - | -$13.90M(+9.0%) | -$52.81M(+5.1%) |
| Mar 2010 | - | -$12.75M(+10.6%) | -$50.26M(+20.8%) |
| Dec 2009 | -$41.61M(+13.9%) | -$11.53M(-21.2%) | -$41.61M(+5.7%) |
| Sep 2009 | - | -$14.63M(+29.0%) | -$39.37M(+10.0%) |
| Jun 2009 | - | -$11.35M(+176.8%) | -$35.80M(+2.5%) |
| Mar 2009 | - | -$4.10M(-55.9%) | -$34.92M(-4.4%) |
| Dec 2008 | -$36.53M(+1353.8%) | -$9.29M(-16.0%) | -$36.53M(+3.1%) |
| Sep 2008 | - | -$11.06M(+5.7%) | -$35.45M(+74.4%) |
| Jun 2008 | - | -$10.47M(+83.2%) | -$20.32M(+42.7%) |
| Mar 2008 | - | -$5.71M(-30.4%) | -$14.24M(+466.8%) |
| Dec 2007 | -$2.51M(-137.4%) | -$8.21M(-301.9%) | -$2.51M(-111.6%) |
| Sep 2007 | - | $4.07M(-192.7%) | $21.74M(+47.7%) |
| Jun 2007 | - | -$4.39M(-172.9%) | $14.72M(-5.5%) |
| Mar 2007 | - | $6.02M(-62.5%) | $15.57M(+131.9%) |
| Dec 2006 | $6.71M(-150.3%) | $16.05M(-643.1%) | $6.71M(-151.9%) |
| Sep 2006 | - | -$2.95M(-16.5%) | -$12.94M(-3.9%) |
| Jun 2006 | - | -$3.54M(+24.5%) | -$13.46M(+3.6%) |
| Mar 2006 | - | -$2.84M(-21.3%) | -$13.00M(-2.6%) |
| Dec 2005 | -$13.35M(+68.0%) | -$3.61M(+3.9%) | -$13.35M(+5.4%) |
| Sep 2005 | - | -$3.48M(+13.1%) | -$12.66M(+7.8%) |
| Jun 2005 | - | -$3.07M(-3.6%) | -$11.74M(+15.0%) |
| Mar 2005 | - | -$3.19M(+9.1%) | -$10.21M(+28.5%) |
| Dec 2004 | -$7.95M(>+9900.0%) | -$2.92M(+14.2%) | -$7.95M(+95.6%) |
| Sep 2004 | - | -$2.56M(+65.8%) | -$4.06M(+156.3%) |
| Jun 2004 | - | -$1.54M(+67.5%) | -$1.59M(-121.8%) |
| Mar 2004 | - | -$920.90K(-195.9%) | $7.26M(<-9900.0%) |
| Dec 2003 | -$49.70K(-10.9%) | $960.40K(-1275.5%) | -$49.70K(-95.3%) |
| Sep 2003 | - | -$81.70K(-101.1%) | -$1.05M(+7.3%) |
| Jun 2003 | - | $7.30M(-188.7%) | -$978.40K(-88.2%) |
| Mar 2003 | - | -$8.23M(>+9900.0%) | -$8.27M(>+9900.0%) |
| Dec 2002 | -$55.80K(+62.2%) | -$39.50K(+276.2%) | -$55.70K(+243.8%) |
| Sep 2002 | - | -$10.50K(-252.2%) | -$16.20K(+184.2%) |
| Jun 2002 | - | $6900.00(-154.8%) | -$5700.00(-54.8%) |
| Mar 2002 | - | -$12.60K | -$12.60K |
| Dec 2001 | -$34.40K | - | - |
FAQ
- What is Halozyme Therapeutics annual free cash flow?
- What is the all time high annual FCF for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual FCF year-on-year change?
- What is Halozyme Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly FCF year-on-year change?
- What is Halozyme Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM FCF year-on-year change?
What is Halozyme Therapeutics annual free cash flow?
The current annual FCF of HALO is $468.37M
What is the all time high annual FCF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual free cash flow is $468.37M
What is Halozyme Therapeutics annual FCF year-on-year change?
Over the past year, HALO annual free cash flow has changed by +$95.09M (+25.47%)
What is Halozyme Therapeutics quarterly free cash flow?
The current quarterly FCF of HALO is $153.27M
What is the all time high quarterly FCF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly free cash flow is $175.41M
What is Halozyme Therapeutics quarterly FCF year-on-year change?
Over the past year, HALO quarterly free cash flow has changed by +$27.39M (+21.76%)
What is Halozyme Therapeutics TTM free cash flow?
The current TTM FCF of HALO is $495.76M
What is the all time high TTM FCF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM free cash flow is $495.76M
What is Halozyme Therapeutics TTM FCF year-on-year change?
Over the past year, HALO TTM free cash flow has changed by +$72.19M (+17.04%)